Harrow Health, Inc. 11.875% Senior Notes due 2027$26.38 %
Analyst Rating: Hold
Stock Details
CEO
Mark L. Baum
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Full Time Employees
217
Address
Nashville
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Top Competitors
Income Statement
Financials
Selected Year
Revenue Estimates
EPS Estimates
Net Income Estimates
Price target for Harrow Health, Inc. 11.875% Senior Notes due 2027 $26.38
$0
Min Forecast(+0% )
$249.61
Avg Forecast( +0% )
$325
Max Forecast(+0%)
EPS
Revenue
Institutional Holder
Loading institutional holder data...
Congress Tracker
Showing 0 of 0 results
Insider Trading of Key Employees
Showing 0 of 0 results